Highlights
About
EV-based Drug Platform to Treat Damage in the Central Nerve System
Nurexone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.
The company is developing a revolutionary biological extracellular vesicles-based technology drug platform to treat damage in the Central Nerve System (CNS). NurExone’s novel approach to SCI treatment is based on the perspective that intranasal exosome administration has broad potential and offers an alternative to other treatments that are under development to treat SCI. Extensive research, conducted at Prof. Shulamit Levenberg’s lab at the Technion, Haifa in collaboration with Prof. Danny Offen from Tel Aviv University tested a novel proprietary treatment using intranasal administration of Exosomes derived from mesenchymal stem cells. Their exosomes were loaded with PTEN siRNA to target complete spinal cord lesion in rats. The research showed significant functional recovery.
Identity
| Name | NurExone Biologic |
|---|---|
| Slug | nurexone-biologic |
| Type / kind | startup |
| Source _id | ATRACPhfHPV90AEahDh0DcP2gsBkQAKvjRUc7bgYgWWksvxsGE7Glo |
Status
| Status | active |
|---|---|
| Status reason | Public on TSXV on Jul 2022; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Haifa |
| HQ address | Haifa, Israel |
Web & social
Classifications
Funding
| Total raised | $9.5M |
|---|---|
| Current stage | Public |
| Market cap | $38.7M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}